Suggested remit - To appraise the clinical and cost effectiveness of SGT320 within its marketing authorisation for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites.
Status Awaiting development
Technology type Medicine
Decision None selected
Process TA
ID number 1278

Email enquiries


Key events during the development of the guidance:

Date Update
27 February 2023 Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled and an update on the revised timelines will be provided when further information is available. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
21 June 2022 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early August 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
15 March 2022 (10:00) Scoping workshop
20 January 2022 - 17 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual